financetom
Business
financetom
/
Business
/
Advent near deal to buy Canadian payments processor Nuvei, source says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Advent near deal to buy Canadian payments processor Nuvei, source says
Mar 16, 2024 2:38 PM

March 16 (Reuters) - Private equity firm Advent

International is in advanced talks to buy Canadian payments

processor Nuvei ( NVEI ), a source familiar with the matter

told Reuters on Saturday.

A deal between the parties could be announced soon, said

the source, who asked not to be named because the discussions

are confidential.

The Wall Street Journal first reported about the potential

deal.

Advent declined to comment. Nuvie did not immediately

respond to Reuters request for comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AI chipmaker Cerebras confidentially files for US IPO
AI chipmaker Cerebras confidentially files for US IPO
Aug 1, 2024
(Reuters) -Artificial intelligence chipmaker Cerebras Systems has confidentially filed for an initial public offering in the United States as it prepares to challenge industry heavyweight Nvidia. The eight-year-old startup will court investors at a time when enthusiasm for AI remains high, boosting the fortunes of firms that supply the infrastructure critical to train chatbots. But Cerebras could face questions about...
ExlService Q2 Adjusted Earnings, Revenue Rise; 2024 Outlook Updated
ExlService Q2 Adjusted Earnings, Revenue Rise; 2024 Outlook Updated
Aug 1, 2024
09:46 AM EDT, 08/01/2024 (MT Newswires) -- ExlService Holdings ( EXLS ) reported Q2 adjusted earnings Thursday of $0.40 per diluted share, compared with $0.36 a year earlier. Analysts polled by Capital IQ expected $0.39. Revenue for the quarter ended June 30 was $448.4 million, compared with $405 million a year earlier. Analysts expected $444.6 million. For 2024, the data...
Dun & Bradstreet Shares Fall as Q2 Revenue Misses Estimates
Dun & Bradstreet Shares Fall as Q2 Revenue Misses Estimates
Aug 1, 2024
09:45 AM EDT, 08/01/2024 (MT Newswires) -- Dun & Bradstreet ( DNB ) shares were falling past 7.7% in recent Thursday trading after the company's Q2 revenue missed analysts' estimates. The company reported Q2 adjusted earnings Thursday of $0.23 per diluted share, up from $0.22 a year earlier. Analysts polled by Capital IQ expected $0.23. Revenue for the quarter ended...
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
Aug 1, 2024
Thursday, Eli Lilly and Company ( LLY ) released topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. HFpEF accounts for nearly half of all heart failure cases, and in the U.S., almost 60%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved